Team 1C

1cBio is an emerging biotechnology company based in the San Francisco Bay Area that focuses on developing precision medicines for significant unmet needs. The company leverages a rational discovery platform to identify and develop small molecules targeting clinically validated mechanisms of action, with a focus on oncology and rare diseases. Its lead programs include OC-1 (also known as ALE1), a first-in-class oral therapeutic for hypophosphatasia partnered with Alesta Therapeutics, and OC-3, a selective PARP1 inhibitor for various solid tumors. 1cBio's strategy involves preemptively countering resistance mechanisms to improve patient outcomes and durability of response.